Biovitrum and Wyeth extend supply agreement

Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto, as well as Xyntha/ReFacto AF, the successor products, and will continue to receive royalties from Wyeth’s global sales. Biovitrum’s co-promotion rights in the Nordic region remain unchanged.

Martin Nicklasson, CEO of Biovitrum, said: “We are very pleased to be able to announce the prolongation of our long and successful collaboration with Wyeth. The agreement enables us to together provide the new improved Xyntha and ReFacto AF internationally, and to improve the lives of hemophilia patients. The agreement validates our biotechnology therapeutic production capabilities and expertise.”